Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

@article{Liepelt2010RivastigmineFT,
  title={Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis},
  author={I Liepelt and Alexandra Gaenslen and Jana Godau and Adriana Di Santo and K. J. Schweitzer and Thomas Gasser and Daniela Berg},
  journal={Alzheimer's \& Dementia},
  year={2010},
  volume={6},
  pages={70-74}
}
Cognitive decline and dementia are present in about 50% of patients with progressive supranuclear palsy (PSP). Based on the known involvement of the cholinergic system in PSP patients, and because rivastigmine, in contrast to other cholinesterase inhibitors, inhibits both acetylcholinesterase and butyrylcholinesterase, we discuss clinical observations of five patients suffering from PSP and dementia who were all treated with rivastigmine over a period of 3 to 6 months. We found a slight… Expand
The Progressive Supranuclear Palsy: Past and Present Aspects
ABSTRACT Objectives: Recently, new criteria for sensitive and specific clinical diagnosis of progressive supranuclear palsy (PSP) have been addressed while distinct clinical phenotypes of theExpand
Progressive Supranuclear Palsy and Dementia
With a prevalence of about 5/100.000, progressive supranuclear palsy is one of the most frequent tauopathies. Clinically, PSP is characterized by early occurrence of severe postural instability andExpand
Progressive supranuclear palsy.
  • L. Golbe
  • Medicine
  • Seminars in neurology
  • 2014
TLDR
Treatment remains supportive, although coenzyme Q-10 has shown preliminary symptomatic efficacy and levodopa may provide transient, modest benefit and magnetic resonance imaging and cerebrospinal fluid measures are showing promise as early-stage screening tools. Expand
Progressive supranuclear palsy.
TLDR
New clinical diagnostic criteria take into account this phenotypic variability in an attempt to diagnose the disease earlier, given the current lack of a validated biomarker. Expand
A case of atypical progressive supranuclear palsy
TLDR
This case highlights the heterogeneity of the clinical features in this syndrome, demonstrating that atypical PSP can present as AOS and aphasia, without the classical features or involvement of the subcortical gray and brainstem region, commonly affected in typical PSP. Expand
Progressive Supranuclear Palsy: New Diagnostic and Therapeutic Strategies
TLDR
The clinical and pathological features of the 7 major phenotypes of PSP are described in addition to new information about the genetic causes of PSP to discuss useful imaging tools, and various management strategies. Expand
[Progressive supranuclear palsy: living environment of the patients in Germany].
TLDR
It is hoped that this investigation has shed more insight into the life and disease-related symptoms of patients with PSP and can provide valuable information for the understanding and treatment of this devastating disease. Expand
Psychiatric symptoms of progressive supranuclear palsy: a case report and brief review
The diagnosis of early-stage progressive supranuclear palsy (PSP) can be very confusing. The psychiatric symptoms associated with neurological and medical conditions including PSP are generally notExpand
Diagnosis and management of progressive supranuclear palsy
SUMMARY Progressive supranuclear palsy is one of the rare ‘atypical parkinsonian’ disorders. It is distinguished by its disproportionate postural instability and multiple supranuclear gaze defectsExpand
Progressive supranuclear palsy: new concepts.
TLDR
The purpose of this review is to help neurologists identify PSP, to better understand its pathophysiology and to provide a more focused, symptom-based treatment approach. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 35 REFERENCES
Donepezil in the treatment of progressive supranuclear palsy
TLDR
Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems, and the lack of effect of donepezil in this disorder is confirmed. Expand
Rivastigmine for dementia associated with Parkinson's disease.
TLDR
Rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor; however, the differences between these two groups were moderate and similar to those reported in trials of rivastIGmine for Alzheimer's disease. Expand
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
TLDR
The findings suggest that acetylcholinesterase inhibitors such as donepezil have at best selective, modest effects on cognition in patients with PSP, and in light of its deleterious effects on ADL/mobility,donepezil is not recommended for this patient population. Expand
Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers
TLDR
Normal brain choline acetyltransferase activity in the 2 patients with severe dementia suggests that, at least in some patients, the cognitive impairment in this disorder is likely to be related to noncholinergic neurotransmitter system changes. Expand
Psychiatric symptoms in progressive supranuclear palsy.
TLDR
This study confirms previous reports of dementia as a common feature ofgressive supranuclear palsy and suggests that psychiatric disturbances, while common, are generally relatively mild, though more serious psychiatric illness may be seen. Expand
The `subcortical dementia' of progressive supranuclear palsy
TLDR
It is proposed as a tentative hypothesis that there may be common pathophysiological mechanisms underlying the subcortical dementias—in particular, disturbances of timing and activation. Expand
Cholinergic cortical circuits in Parkinson’s disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study
TLDR
It is demonstrated that the excitability of the motor cortex is differentially modulated by sensory afferents in PD and PSP and may indicate that the mechanisms of cholinergic dysfunction are different between the two diseases. Expand
Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
TLDR
Part of the clinical symptomatology in PSP could be relieved by the enhancement of brain cholinergic neurotransmission, and the precise pathophysiology of these physostigmine-induced effects needs further investigations. Expand
Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.
TLDR
In PSP, the variance in frontal grey matter volume related to measures of behavioural disturbance, confirming the use of behavioural tests for ante-mortem case differentiation and suggesting that intrinsic cortical deficits contribute to these clinical disturbances. Expand
Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.
Regional brain volumes were measured in 21 patients with progressive supranuclear palsy (PSP), 17 patients with Parkinson's disease and 23 controls using 3D MRI-based volumetry. Cortical, subcorticalExpand
...
1
2
3
4
...